Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.4.2.30 (PARP)
 13,611 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Carbon nanotubes (CNTs) are emerging nanotechnology materials which are likely to be mass-produced in the near future. However, prior to mass-production, certain health-related concerns should first be addressed. For example, when inhaled, the thin-fibrous shape and the biopersistent characteristics of CNTs may cause pulmonary diseases, in a manner similar to asbestos. In the present study, mouse macrophages (J774.1) were exposed to highly-purified multi-walled CNTs (MWCNTs, 67 nm) or to UICC crocidolite in order to evaluate the toxicity of these nano-size fibers. The cytotoxicity of MWCNTs was found to be higher than that of crocidolite. The toxic effect of MWCNTs was not affected by N-acetylcysteine, an antioxidant, or buthionine sulfoximine, a glutathione synthesis inhibitor. cDNA microarray analyses suggested that the cytotoxicity of MWCNTs could not be explained satisfactorily by either an increase or decrease of gene expression, although mRNA levels of some cytokines were slightly increased by MWCNTs. Moreover, MWCNTs did not significantly activate either MAP kinases such as ERK, JNK and p38, nor common apoptosis pathways such as caspase 3 and PARP. Electron microscopic studies indicated that MWCNTs associate with the plasma membrane of macrophages and disrupt the integrity of the membrane. Several proteins were found to adsorb onto MWCNTs when MWCNT-exposed macrophages were gently lysed. One of these proteins was macrophage receptor with collagenous structure (MARCO). MARCO-transfected CHO-K1 cells associated with MWCNTs more rapidly than mock-transfected cells. These results indicate that MWCNTs probably trigger cytotoxic effects in phagocytotic cells by reacting with MARCO on the plasma membrane and rupturing the plasma membrane.
 ...
PMID:Multi-walled carbon nanotubes injure the plasma membrane of macrophages. 1865 3

Carbon nanotubes (CNTs) have attracted great interest with respect to biomaterials, particularly for use as an implant material in bone-tissue engineering. Accordingly, the bone-tissue compatibility of CNTs and their influence on new bone formation are important issues. In the present study, we examined the effects of multi-wall carbon nanotubes (MWCNTs) on the receptor activator of nuclear factor kappaB ligand (RANKL)-supported osteoclastogenesis using a murine monocytic cell line RAW 264.7. MWCNTs significantly suppressed the differentiation of RAW 264.7 cells into osteoclasts. Treatment with MWCNTs induced apoptosis in osteoclasts as characterized by nuclear condensation, DNA fragmentation, caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage, but did not decrease the cell viability of the osteoblast-like cell line MC3T3-E1. MWCNTs also induced loss of the mitochondrial membrane potential (deltapsim) by regulating expression of Bcl-2 family proteins and caused release of cytochrome c from mitochondria to cytosol. MWCNTs-induced apoptosis in osteoclasts was inhibited both by cyclosporin A, a blocker of the mitochondrial permeability transition pore, and by DEVD-CHO, a cell-permeable inhibitor of caspase-3. The present study suggests that MWCNTs suppresse osteoclastogenesis via the inhibition of osteoclast differentiation and the induction of apoptosis in osteoclasts, rendering them promising candidate for the treatment of osteoclast-related diseases.
 ...
PMID:Multi-walled carbon nanotubes induce apoptosis in RAW 264.7 cell-derived osteoclasts through mitochondria-mediated death pathway. 2275 27

The clinical application of carbon ions generated by the heavy ion medical accelerator in Chiba (HIMAC) reached its 20th anniversary in 2014. More than 9,000 cancer patients have been treated at the National Institute of Radiological Sciences (NIRS). Carbon-ion radiotherapy has been applied for treating various types of tumors that were considered difficult to control with existing modalities. Our experience to date has indicated that carbon-ion radiotherapy is advantageous for head and neck cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, bone/soft tissue sarcomas of the pelvis, uterine cervix adenocarcinomas, and other cancers. However, some cancer types (such as those in close proximity to radiosensitive normal organs) require additional treatments to sensitize the target cancer because of limitation of the irradiation dose. Furthermore, systemic combined therapy is also utilized to suppress possible metastasis. Currently, some anticancer agents are utilized with carbon-ion radiotherapy, including dacarbazine, nimustine hydrochloride, vincristine (DAV), gemcitabine, cisplatin, and 5-fluorouracil. Interesting reagents such as PARP and HSP90 inhibitors have been proposed as cancer cell- specific sensitizers for carbon-ion irradiation during basic biological studies, especially those from the Research Project with Heavy Ions at NIRS-HIMAC. In our laboratory, we have focused our studies on the suppression of metastasis. We have proposed the concurrent use of reagents to inhibit the invasive potential of cancer cells under carbon-ion irradiation. Recently, we have also shown that combining carbon-ion radiotherapy with the local injection of dendritic cells inhibits lung metastases in an in vivo murine model.
 ...
PMID:[Treatment with carbon-ion radiotherapy and its combinations -- basic biological studies and investigations at the National Institute of Radiological Sciences]. 2574 34

Chondrosarcoma is a malignant tumor that arises from cartilaginous tissue and is radioresistant and chemoresistant to conventional treatments. The preferred treatment consists of surgical resection, which might cause severe disabilities for the patient; in addition, this procedure might be impossible for inoperable locations, such as the skull base. Carbon ion irradiation (hadron therapy) has been proposed as an alternative treatment, primarily due to its greater biological effectiveness and improved ballistic properties compared with conventional radiotherapy with X-rays. The goal of this study was to characterize the genetic mutations of a grade III chondrosarcoma cell line (CH2879) and examine the cellular responses to conventional radiotherapy (X-rays) and hadron therapy (proton and carbon ions) in the presence of the PARP inhibitor Olaparib. To better understand PARP inhibition, we first analyzed the formation of poly-ADP ribose chains by western blot; we observed an increase in its signal after irradiation, which disappeared on addition of the PARP inhibitor. PARPi enhanced ratio of approximately 1.3, 1.8, and 1.5 following irradiation of cells with X-rays, protons, and C-ions, respectively, as detected by clonogenic assay. The decrease in cell survival was confirmed by proliferation assay. The radiosensitivity of CH2879 cells was associated with mutations in homologous recombination repair genes, such as RAD50, SMARCA2 and NBN. This study demonstrates the capacity of the PARP inhibitor Olaparib to radiosensitize mutated chondrosarcoma cells to conventional photon irradiation, proton and carbon ion irradiation.
 ...
PMID:Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation. 3131 95